KEY TAKEAWAYS
- The study aimed to investigate the prognostic significance of sCD73 expression in IDC subtypes.
- Researchers noticed high sCD73 correlates with poor prognosis in IDC, particularly in luminal subtypes, further investigation is ongoing.
Invasive ductal carcinoma (IDC) encompasses various subtypes, each with distinct prognoses and treatment responses. For example, triple-negative breast cancer (TNBC) generally has worse outcomes compared to other subtypes. Prior research has highlighted the role of interstitial CD73 in tumor invasion and prognosis across different cancers.
Masumi Tanaka and the team aimed to evaluate stromal CD73 (sCD73) expression in IDC and its potential prognostic relevance.
They performed an inclusive analysis of 61 cases of human epidermal growth factor receptor 2-negative IDC, including both TNBC and hormone receptor-positive (luminal-type) cases, which were surgically treated. Cases that had received preoperative drug therapy were excluded. CD73 expression was assessed through immunostaining of the tumor stroma.
About 70% of all cases exhibited sCD73 expression, with a notably higher prevalence in TNBC (93%) compared to luminal breast cancer (48%). Elevated sCD73 expression correlated with poor prognosis regarding overall survival (OS) and disease-free survival (DFS) across all cases. In patients with luminal breast cancer, high sCD73 expression also signified poor prognosis for both OS and DFS.
The study concluded that high expression of sCD73 is linked to poor prognosis in IDC, especially in luminal breast cancer. Further research is necessary to validate sCD73 as an independent prognostic factor.
No funding information was given.
Source: https://pubmed.ncbi.nlm.nih.gov/39060073/
Tanaka M, Aoki M, Masuda Y, et al. (2024). “Stromal CD73 Expression in Breast Cancer: Subtype-specific Expression and its Prognostic Significance.” Anticancer Res. 2024 Aug;44(8):3637-3643. doi: 10.21873/anticanres.17187. PMID: 39060073.
